Search

This paper presents a novel approach to enhance the accuracy of patch-level Gleason grading in prostate histopathology images, a critical task in the diagnosis and prognosis of prostate cancer. This study shows that the Gleason grading accuracy can be improved by addressing the prevalent issue of label inconsistencies in the SICAPv2 prostate dataset, which employs a majority voting scheme for patch-level labels. We propose a multi-label ensemble deep-learning classifier that effectively mitigates these inconsistencies and yields more accurate results than the state-of-the-art works. Specifically, our approach leverages the strengths of three different one-vs-all deep learning models in an ensemble to learn diverse features from the histopathology images to individually indicate the presence of one or more Gleason grades (G3, G4, and G5) in each patch. These deep learning models have been trained using transfer learning to fine-tune a variant of the ResNet18 CNN classifier chosen after an extensive ablation study. Experimental results demonstrate that our multi-label ensemble classifier significantly outperforms traditional single-label classifiers reported in the literature by at least 14% and 4% on accuracy and f1-score metrics respectively. These results underscore the potential of our proposed machine learning approach to improve the accuracy and consistency of prostate cancer grading. [ABSTRACT FROM AUTHOR]

Background: Cancer diagnosis based on machine learning has become a popular application direction. Support vector machine (SVM), as a classical machine learning algorithm, has been widely used in cancer diagnosis because of its advantages in high-dimensional and small sample data. However, due to the high-dimensional feature space and high feature redundancy of gene expression data, SVM faces the problem of poor classification effect when dealing with such data. Methods: Based on this, this paper proposes a hybrid feature selection algorithm combining information gain and grouping particle swarm optimization (IG-GPSO). The algorithm firstly calculates the information gain values of the features and ranks them in descending order according to the value. Then, ranked features are grouped according to the information index, so that the features in the group are close, and the features outside the group are sparse. Finally, grouped features are searched using grouping PSO and evaluated according to in-group and out-group. Results: Experimental results show that the average accuracy (ACC) of the SVM on the feature subset selected by the IG-GPSO is 98.50%, which is significantly better than the traditional feature selection algorithm. Compared with KNN, the classification effect of the feature subset selected by the IG-GPSO is still optimal. In addition, the results of multiple comparison tests show that the feature selection effect of the IG-GPSO is significantly better than that of traditional feature selection algorithms. Conclusion: The feature subset selected by IG-GPSO not only has the best classification effect, but also has the least feature scale (FS). More importantly, the IG-GPSO significantly improves the ACC of SVM in cancer diagnostic. [ABSTRACT FROM AUTHOR]

One of the important tasks in cancer research is to identify biomarkers and build classification models for clinical outcome prediction. In this paper, we develop a CyNetSVM software package, implemented in Java and integrated with Cytoscape as an app, to identify network biomarkers using network-constrained support vector machines (NetSVM). The Cytoscape app of NetSVM is specifically designed to improve the usability of NetSVM with the following enhancements: (1) user-friendly graphical user interface (GUI), (2) computationally efficient core program and (3) convenient network visualization capability. The CyNetSVM app has been used to analyze breast cancer data to identify network genes associated with breast cancer recurrence. The biological function of these network genes is enriched in signaling pathways associated with breast cancer progression, showing the effectiveness of CyNetSVM for cancer biomarker identification. The CyNetSVM package is available at Cytoscape App Store and ; a sample data set is also provided at sourceforge.net. [ABSTRACT FROM AUTHOR]

The current research study is concerned with the automated differentiation between histopathological slides from colon tissues with respect to four classes (healthy tissue and cancerous of grades 1, 2 or 3) through an optimized ensemble of predictors. Six distinct classifiers with prediction accuracies ranging from 87% to 95% are considered for the task. The proposed method of combining them takes into account the probabilities of the individual classifiers for each sample to be assigned to any of the four classes, optimizes weights for each technique by differential evolution and attains an accuracy that is significantly better than the individual results. Moreover, a degree of confidence is defined that would allow the pathologists to separate the data into two distinct sets, one that is correctly classified with a high level of confidence and the rest that would need their further attention. The tandem is also validated on other benchmark data sets. The proposed methodology proves to be efficient in improving the classification accuracy of each algorithm taken separately and performs reasonably well on other data sets, even with default weights. In addition, by establishing a degree of confidence the method becomes more viable for use by actual practitioners. [ABSTRACT FROM AUTHOR]

Several computer aided diagnosis (CAD) systems have been developed for mammography. They are widely used in certain countries such as the U.S. where mammography studies are conducted more frequently; however, they are not yet globally employed for clinical use due to their inconsistent performance, which can be attributed to their reliance on hand-crafted features. It is difficult to use hand-crafted features for mammogram images that vary due to factors such as the breast density of patients and differences in imaging devices. To address these problems, several studies have leveraged a deep convolutional neural network that does not require hand-crafted features. Among the recent object detectors, RetinaNet is particularly promising as it is a simpler one-stage object detector that is fast and efficient while achieving state-of-the-art performance. RetinaNet has been proven to perform conventional object detection tasks but has not been tested on detecting masses in mammograms. Thus, we propose a mass detection model based on RetinaNet. To validate its performance in diverse use cases, we construct several experimental setups using the public dataset INbreast and the in-house dataset GURO. In addition to training and testing on the same dataset (i.e., training and testing on INbreast), we evaluate our mass detection model in setups using additional training data (i.e., training on INbreast + GURO and testing on INbreast). We also evaluate our model in setups using pre-trained weights (i.e., using weights pre-trained on GURO, training and testing on INbreast). In all the experiments, our mass detection model achieves comparable or better performance than more complex state-of-the-art models including the two-stage object detector. Also, the results show that using the weights pre-trained on datasets achieves similar performance as directly using datasets in the training phase. Therefore, we make our mass detection model’s weights pre-trained on both GURO and INbreast publicly available. We expect that researchers who train RetinaNet on their in-house dataset for the mass detection task can use our pre-trained weights to leverage the features extracted from the datasets. [ABSTRACT FROM AUTHOR]

Gastric cancer is the third leading cause of cancer-related mortality worldwide and despite advances in prevention, diagnosis and therapy, it is still regarded as a global health concern. The efficacy of the therapies for gastric cancer is limited by a poor response to currently available therapeutic regimens. One of the reasons that may explain these poor clinical outcomes is the highly heterogeneous nature of this disease. In this sense, it is essential to discover new molecular agents capable of targeting various gastric cancer subtypes simultaneously. Here, we present a multi-objective approach for the ligand-based virtual screening discovery of chemical compounds simultaneously active against the gastric cancer cell lines AGS, NCI-N87 and SNU-1. The proposed approach relays in a novel methodology based on the development of ensemble models for the bioactivity prediction against each individual gastric cancer cell line. The methodology includes the aggregation of one ensemble per cell line using a desirability-based algorithm into virtual screening protocols. Our research leads to the proposal of a multi-targeted virtual screening protocol able to achieve high enrichment of known chemicals with anti-gastric cancer activity. Specifically, our results indicate that, using the proposed protocol, it is possible to retrieve almost 20 more times multi-targeted compounds in the first 1% of the ranked list than what is expected from a uniform distribution of the active ones in the virtual screening database. More importantly, the proposed protocol attains an outstanding initial enrichment of known multi-targeted anti-gastric cancer agents. [ABSTRACT FROM AUTHOR]